Failure of secretion of the incretin hormone glucagon-like peptide-1 (GLP-1) plays a
prominent role in type 2 diabetes, and restoration of GLP-1 action is an important therapeutic …

Established therapies for type‐2 diabetes effectively reduce blood glucose, but are often
associated with adverse effects that pose risks to patient's health or diminish adherence to …

Objective The role of glucagon-like peptide-1 (GLP-1) receptor agonists in the treatment of
type 2 diabetes is debated; many recent trials, which were not included in previous meta …

Introduction: Recently, glucagon-like peptide-1 receptor (GLP-1R) agonists have become
available for the treatment of type 2 diabetes. These agents exploit the physiological effects …

Novel therapeutic options for type 2 diabetes mellitus based on the action of the incretin
hormone glucagon-like peptide (GLP)-1 were introduced in 2005. As injectable GLP-1 …

Abstract Introduction Glucagon-like peptide-1 (GLP-1) has been the focus of considerable
research activity in the treatment of type 2 diabetes mellitus (T2DM) because the incretin …

Introduction: GLP-1 receptor agonists have been shown to be effective in the treatment of
type 2 diabetes mellitus (T2DM). Although the first GLP-1 receptor agonist, exenatide, was …

Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists are a valuable addition to
the type 2 diabetes armamentarium. They increase insulin secretion and reduce glucagon …

Introduction: Within recent years, glucagon-like peptide 1 receptor agonists (GLP-1-RA)
have emerged as a new treatment option for type 2 diabetes. The GLP-1-RA are …

Incretin-based therapies are important addition to our armamentarium for the treatment of
type 2 diabetes (T2DM). There are six Glucagon-like peptide-1 receptor agonists (GLP …